RE: Again mms won’t stop tidal wave this afternoon 👊6 Nov 2023 09:18
Information for Potential Investors - Part Two5 Nov 2023 13:16
Porky9 Premium Member
Posted in: VAL
Posts: 6,358
Price: 52.50
Strong Buy
Information for Potential Investors - Part Two26 Oct 2021 06:31
THIS IS AN INFORMATION REPOST FOR NEW INVESTORS
(Again, Apologies to regulars that have seen this post before but its essential new visitors thinking about investing see it )
Very Quick Synopsis:
An incredibly promising Biotech that accelerates the development of treatments in cancer and women’s health to improve patient lives.
They select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic to investor-ready assets.
They do not YET have a commercially viable drug but have made significant progress developing both legacy and more recent drug candidates. They are on the cusp of licence deals being completed before the end of this year. The CEO in the Pod Cast with Zac Mir last Sunday confirmed that it will be announceable shortly hence, the increasing interest in the business and increased trading volumes.
The current drug stable includes:
* VAL401 lung/pancreatic cancer drug candidate
* VAL 201 prostate cancer drug candidate
* VAL301 endometriosis drug
* BC201 A Peptide repurposed for anti-inflammatory use
* Lastly, the company’s recent partnership with a London university has its triple-negative breast cancer drug under evaluation, after which Valirx could license the technology under pre-agreed terms.
The clinical results out last September for 201 were great and the recent presentation absolutely fantastic so its all looking good.
BC201 gets largely overlooked by shareholders but could also be a hidden gem. Data due any moment. It could prove to materially reduce long term Covid damage and/or Sepsis, One to watch:
https://www.valirx.com/sites/default/files/2020-10/BlackCat-COVID-19-ARDS-treatment-summary.pdf
As a bonus the share price at 53p represents a mere £34m Market Cap. The peer average at this point is £ 52m an 80p share price hence, the Biotech is materially undervalued, still +50% increase to go just to the average point plus the stratospheric rises on license terms expected. Also, we have three projects on the brink of licensing, just the one licence deal should come in at many multiples of the current market cap and see us firmly in the £1 to £2 range hence, all to play for.
It's a Red Hot Buy and one of the best risk reward investments on the AIM in my considered opinion but DYOR.
Oh and finally, least I forget, the CEO here is just amazing, new team, new ethos and really cares about the shareholders. Which is totally refreshing compared to others on AIM.
That about covers it but DYOR and follow the links in the previous post.
Good Luck
Pork’s
Sign In
Follow the stocks
